We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

EZPW:NASDAQEZCORP, Inc. Analysis

Data as of 2026-04-01 - not real-time

$26.02

Latest Price

5/10Risk

Risk Level: Medium

Executive Summary

EZCORP’s price is firmly above its 20‑day (25.77) and 50‑day (24.68) moving averages and the longer‑term 200‑day SMA (19.16) remains well below current levels, confirming a bullish trend despite a modest RSI of 56. The MACD histogram is negative and the signal line is bearish, while volume is on a decreasing trajectory, suggesting that short‑term momentum may be softening. Nonetheless, the stock has rallied roughly 25% over the past month and an insider purchase by board member Jason A. Kulas adds confidence to the upside narrative.
Fundamentally, EZCORP delivers solid growth with 19.3% revenue expansion, healthy gross margins (~58.6%) and operating margins near 16%. Valuation appears fair – the trailing PE of 16.57 aligns with the industry average of 16.53, while the forward PE contracts to 12.77, indicating upside potential of about 26%. The balance sheet shows ample cash ($466 M) against debt ($767 M), though the debt‑to‑equity ratio of 71.6% warrants monitoring. With a low beta of 0.33, modest 30‑day volatility (~30%), and an “Extreme Greed” sentiment index, the stock sits at a reasonable risk‑reward balance for investors.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 7/10

Key Factors

  • Bullish SMA alignment supports price stability
  • Recent insider purchase signals confidence
  • MACD bearish divergence and falling volume suggest caution

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • Strong revenue growth and improving margins
  • Forward PE of 12.77 indicates valuation upside
  • Low beta and moderate volatility reduce market risk

Long Term

> 3 years
Neutral
Model confidence: 6/10

Key Factors

  • Solid cash position but elevated debt‑to‑equity ratio
  • Diversified geographic footprint adds growth avenues
  • Stable business model with no dividend reliance

Key Metrics & Analysis

Financial Health

Revenue Growth19.30%
Profit Margin9.20%
P/E Ratio16.6
ROE12.97%
ROA6.06%
Debt/Equity71.63
P/B Ratio1.5
Op. Cash Flow$162.1M
Free Cash Flow$17.2M
Industry P/E16.5

Technical Analysis

TrendBullish
RSI56.1
Support$24.38
Resistance$26.91
MA 20$25.77
MA 50$24.68
MA 200$19.16
MACDBearish
VolumeDecreasing
Fear & Greed Index77.61

Valuation

Fair Value$3.44
Target Price$32.80
Upside/Downside26.06%
GradeFair
TypeBlend

Risk Assessment

Beta0.33
Volatility29.88%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.